Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Clarius Group LLC

Clarius Group LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 620 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. Clarius Group LLC’s holdings in Regeneron Pharmaceuticals were worth $442,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Rakuten Securities Inc. lifted its holdings in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the period. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter worth $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals during the third quarter valued at $37,000. Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter valued at $39,000. Finally, Itau Unibanco Holding S.A. purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at $42,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $681.58 on Monday. The stock has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a 50 day simple moving average of $738.60 and a 200-day simple moving average of $949.32. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20.

Analysts Set New Price Targets

A number of research firms have recently commented on REGN. Barclays dropped their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $1,130.00 to $738.00 in a research report on Thursday. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Finally, Oppenheimer reduced their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.